Aptabio Therapeutics Inc.

Aptabio Therapeutics develops platform drugs targeting oxidative stress, cancer-associated fibroblasts, and aptamer conjugates to treat diabetes complications, vascular & neurodegenerative diseases, and hard‑to‑treat cancers. Based in Yongin‑si, South Korea.

Headquarters: South Korea (KOR)

Aptabio Therapeutics Inc. Logo
Company Profile
  • HQ: Yongin-si
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
293780 Aptabio Therapeutics Inc.
Cap: 240.1B
EQUITY KOE KRW KR7293780003 Active
📈
Home Login